Sign in
PTIX Stock Price, Chart, Stats & News
Protagenic Therapeutics, Inc.
Save
Protagenic Therapeutics, Inc. (PTIX) does not currently pay a dividend.
709,602
Market cap
–
Current P/E
–
Forward P/E
PTIX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -241.84% |
ROE | 184.88% |
D/E | -1.32x |
Interest coverage ratio | -21.36x |
PTIX valuation
P/E | – |
P/S | – |
P/B | -0.42x |
P/CF | -0.24x |
P/FCF | -0.24x |
P/OCF | -0.24x |
PEG | -0.01x |
EV multiple | -0.01x |
About
Protagenic Therapeutics, Inc. operates as a biopharmaceutical firm dedicated to the research and development of novel treatments designed to address neuropsychiatric and mood conditions exacerbated by stress. Foremost among its investigational products is PT00114, a laboratory-synthesized version of the teneurin carboxy-terminal associated peptide. This compound functions by emulating an innate brain signaling peptide, known for its ability to temper exaggerated stress reactions.
Similar securities
Based on sector and market capitalization
Report issue